SOHO 2024: Focus on AML
The phase III SIERRA trial compared Iomab-B-led allogeneic HSCT with conventional care in older patients with AML.
The prognostic significance of mNPM1 MRD is greatest in AML patients with concomitant FLT3-ITD.
Some interventions such as PARP inhibitors can cause adverse events, but others such as HSCT can benefit patients.
Advertisement
Sorafenib, a FLT3 inhibitor, led to significantly improved survival compared with placebo in patients with AML.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.